The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis.

MLA

Tan, Bee K., et al. “The Anti-Atherogenic Aspect of Metformin Treatment in Insulin Resistant Women with the Polycystic Ovary Syndrome: Role of the Newly Established pro-Inflammatory Adipokine Acute-Phase Serum Amyloid A; Evidence of an Adipose Tissue-Monocyte Axis.” Atherosclerosis, vol. 216, no. 2, June 2011, pp. 402–08. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2010.08.069.

APA

Tan, B. K., Adya, R., Shan, X., Aghilla, M., Lehnert, H., Keay, S. D., & Randeva, H. S. (2011). The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. Atherosclerosis, 216(2), 402–408. https://doi.org/10.1016/j.atherosclerosis.2010.08.069

Chicago

Tan, Bee K, Raghu Adya, Xiaoye Shan, Mohamed Aghilla, Hendrik Lehnert, Stephen D Keay, and Harpal S Randeva. 2011. “The Anti-Atherogenic Aspect of Metformin Treatment in Insulin Resistant Women with the Polycystic Ovary Syndrome: Role of the Newly Established pro-Inflammatory Adipokine Acute-Phase Serum Amyloid A; Evidence of an Adipose Tissue-Monocyte Axis.” Atherosclerosis 216 (2): 402–8. doi:10.1016/j.atherosclerosis.2010.08.069.